Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 4/30/26 | AstraZeneca (AZN) | camizestrant for HR+/HER2- Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/30/26 | AstraZeneca (AZN) | Truqap for Prostate Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/27/26 | Mundipharma | Rezzayo for Fungal Infections - Systemic | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/27/26 | Mundipharma | Rezzayo for Candidiasis | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/27/26 | Compass Therapeutics (CMPX) | tovecimig for Biliary Tract Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/08/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/17/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |